These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29264970)

  • 41. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations.
    Igietseme JU; Eko FO; Black CM
    Expert Rev Vaccines; 2011 Nov; 10(11):1585-96. PubMed ID: 22043957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chlamydia trachomatis: the Persistent Pathogen.
    Witkin SS; Minis E; Athanasiou A; Leizer J; Linhares IM
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28835360
    [No Abstract]   [Full Text] [Related]  

  • 43. [Chlamydia trachomatis infections].
    Széll A; Szalka A
    Orv Hetil; 1998 Nov; 139(46):2767-73. PubMed ID: 9849062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection.
    Howie SE; Horner PJ; Horne AW; Entrican G
    Curr Opin Infect Dis; 2011 Feb; 24(1):56-61. PubMed ID: 21124214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Chlamydia trachomatis urogenital infections in women. Best diagnostic approaches].
    Hamdad F; Orfila J; Boulanger JC; Eb F
    Gynecol Obstet Fertil; 2004 Dec; 32(12):1064-74. PubMed ID: 15589784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Male genital tract chlamydial infection: implications for pathology and infertility.
    Cunningham KA; Beagley KW
    Biol Reprod; 2008 Aug; 79(2):180-9. PubMed ID: 18480466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overview of Chlamydia trachomatis infection and the requirements for a vaccine.
    Schachter J
    Rev Infect Dis; 1985; 7(6):713-6. PubMed ID: 3840910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chlamydial pelvic inflammatory disease.
    Paavonen J; Lehtinen M
    Hum Reprod Update; 1996; 2(6):519-29. PubMed ID: 9111185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates.
    Vasilevsky S; Stojanov M; Greub G; Baud D
    Virulence; 2016; 7(1):11-22. PubMed ID: 26580416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
    Müller T; Becker E; Stallmann S; Waldhuber A; Römmler-Dreher F; Albrecht S; Mohr F; Hegemann JH; Miethke T
    Vaccine; 2017 May; 35(21):2801-2810. PubMed ID: 28413133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Future prospects for new vaccines against sexually transmitted infections.
    Gottlieb SL; Johnston C
    Curr Opin Infect Dis; 2017 Feb; 30(1):77-86. PubMed ID: 27922851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing pelvic infection after abortion.
    Stevenson MM; Radcliffe KW
    Int J STD AIDS; 1995; 6(5):305-12. PubMed ID: 8547409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chlamydia trachomatis infection in sexually active adolescents and young women.
    Filipp E; Raczyński P; El Midaoui A; Pawłowska A; Tarnowska-Madra U; Scholz A; Niemiec KT; Chamerski J
    Med Wieku Rozwoj; 2005; 9(1):57-64. PubMed ID: 16082066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Netherlands Chlamydia cohort study (NECCST) protocol to assess the risk of late complications following Chlamydia trachomatis infection in women.
    Hoenderboom BM; van Oeffelen AA; van Benthem BH; van Bergen JE; Dukers-Muijrers NH; Götz HM; Hoebe CJ; Hogewoning AA; van der Klis FR; van Baarle D; Land JA; van der Sande MA; van Veen MG; de Vries F; Morré SA; van den Broek IV
    BMC Infect Dis; 2017 Apr; 17(1):264. PubMed ID: 28399813
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chlamydia trachomatis infection: host immune responses and potential vaccines.
    Hafner L; Beagley K; Timms P
    Mucosal Immunol; 2008 Mar; 1(2):116-30. PubMed ID: 19079169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Chlamydia trachomatis in the reproductive setting: British Fertility Society Guidelines for practice.
    Akande V; Turner C; Horner P; Horne A; Pacey A;
    Hum Fertil (Camb); 2010 Sep; 13(3):115-25. PubMed ID: 20849196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women.
    Lea AP; Lamb HM
    Pharmacoeconomics; 1997 Nov; 12(5):596-611. PubMed ID: 10174326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chlamydia trachomatis as the Cause of Infectious Infertility: Acute, Repetitive or Persistent Long-Term Infection?
    Schuchardt L; Rupp J
    Curr Top Microbiol Immunol; 2018; 412():159-182. PubMed ID: 27370345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women.
    Menon S; Timms P; Allan JA; Alexander K; Rombauts L; Horner P; Keltz M; Hocking J; Huston WM
    Clin Microbiol Rev; 2015 Oct; 28(4):969-85. PubMed ID: 26310245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genital chlamydial infections: epidemiology and reproductive sequelae.
    Cates W; Wasserheit JN
    Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 2):1771-81. PubMed ID: 2039031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.